Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Authors :: Mathilde, Hunault-Berger
Pautas, Cécile
Bertoli, Sarah
Dumas, Pierre-Yves
Raffoux, Emmanuel
Marchand, Tony
Hospital, Marie Anne
Heiblig, Mael
Chantepie, Sylvain
Carré, Martin
Peterlin, Pierre
Lemasle, Emilie
Simand, Célestine
Gallego Hernanz, Maria Pilar
Huynh, Anne
Forcade, Edouard
Devillier, Raynier
Nguyen Quoc, Stéphanie
Duployez, Nicolas
Luquet, Isabelle
Penther, Dominique
Celli-Lebras, Karine
Mineur, Ariane
Gardin, Claude
Socié, Gerard
Cahn, Jean-Yves
Ifrah, Norbert
Vey, Norbert
Peffault De Latour, Regis
Delabesse, Eric
Preudhomme, Claude
Hamel, Jean-François
Pigneux, Arnaud
Recher, Christian
Dombret, Hervé
Source :: Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p967-967, 1p
Publication Year :: 2023
Abstract: Introduction. This multicenter study randomly explored various standard intensive chemotherapy (ICT) strategies in adults with AML, namely higher-dose idarubicin (IDA) vshigh-dose daunorubicin (DNR) and intermediate-dose (IDAC) vshigh-dose (HDAC) cytarabine. The study was planned large enough to allow patient subgroup analysis.

Full Text Access

Tools